Anti-CD1a Antibody, clone 3J8 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed, and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 3J8 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects CD1a. It targets an epitope within 25 amino acids from the N-terminal, extracellular domain.

KLH-conjugated linear peptide corresponding to 25 amino acids from the N-terminal, extracellular domain of human CD1a.

Quality Control Testing

Evaluated by Western Blotting in Jurkat cell lysate.

Western Blotting Analysis: A 1:10,000 dilution of this antibody detected CD1a in Jurkat cell lysate.

Tested Applications

Western Blotting Analysis: A 1:10,000 dilution from a representative lot detected CD1a in lysate from MOLT-4 cells.

Affinity Binding Assay: A representative lot of this antibody bound with CD1a peptide at least ten million-fold (10,000,000X) higher affinity than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:1,000 dilution from a representative lot detected CD1a in MOLT-4 cells.

Flow Cytometry Analysis: 0.1 µg from a representative lot detected CD1a in one million Jurkat cells.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

T-cell surface glycoprotein CD1a (UniProt: P06126; also known as T-cell surface antigen T6/Leu-6 (hTa1 thymocyte antigen), CD1a) is encoded by the CD1A gene (Gene ID: 909) in human. CD1a is a transmembrane glycoprotein belonging to the CD1 family of antigen-presenting molecules. These are evolutionary conserved proteins which present lipids instead of peptide. CD1a is composed of a heavy chain that forms a binding groove for lipid antigens, associated with a β2-microglobulin light chain. CD1a plays a crucial role in the presentation of lipid antigens to T cells, particularly to a subset of T cells known as natural killer T (NKT) cells. It helps bridge innate and adaptive immunity by presenting non-peptidic antigens, thus activating T cells and promoting immune responses against certain pathogens. CD1a is primarily expressed on the surface of dendritic cells, thymocytes, and certain subsets of T cells. Its expression is particularly prominent during the early stages of T cell development in the thymus, as well as in peripheral tissues involved in immune responses. Alterations in CD1a expression and function have been associated with various diseases, including autoimmune disorders and infections. In conditions such as psoriasis, CD1a expression is upregulated, contributing to the inflammatory response. Additionally, its role in lipid antigen presentation makes it relevant in the context of certain infections and cancers, where CD1a may influence immune evasion and tumor progression. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.